Mereo BioPharma (MREO) EBIT Margin (2023 - 2025)
Mereo BioPharma (MREO) posted quarterly EBIT Margin of 2099.8% for Q2 2025, down 194.58% quarter-over-quarter from 712.8% in Q4 2023.
Mereo BioPharma (MREO) EBIT Margin (2023 - 2025) Analysis & Trends
Mereo BioPharma (MREO) has reported EBIT Margin for 2 consecutive years, with 2099.8% the latest figure, recorded in Q2 2025.
- In Q2 2025, EBIT Margin changed N/A year-over-year to 2099.8%; the TTM figure through Dec 2025 stood at 8021.2% (changed N/A YoY), while the FY2025 annual figure was 8021.4%, changed N/A from the prior year.
- EBIT Margin slipped to 2099.8% in Q2 2025 per MREO's latest filing, from 712.8% in the prior quarter.
- Across five years, EBIT Margin topped out at 9.01% in Q2 2023 and bottomed at 2099.8% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Mereo BioPharma | 47.15 Mn | 47.15 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2,099.80% |
| Dec 31, 2023 | -712.80% |
| Jun 30, 2023 | -9.01% |